Lytix Biopharma Investor Relations Material
Latest events
Q4 2023
Lytix Biopharma
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from Lytix Biopharma
Access all reports
Segment Data
Access more data
Operating income by
Geography
U.S.
Norway
Expenses by
Financials
Lytix Biopharma ASA, a clinical stage biotech company, develops novel cancer immunotherapies for the local treatment of solid tumors that is in Phase II clinical trials. Its lead product candidate is LTX-315, an oncolytic molecule that is designed for intratumoral injections and targeting deep-seated lesions such as liver cancer. The company has strategic partnership with Aurelius Biotherapeutics LLC to investigate and develop LTX-122 for the veterinary medicine market.
Key slides for Lytix Biopharma
Study Update
Lytix Biopharma
Q4 2023
Lytix Biopharma
Latest articles
Sergey Brin's Role in Shaping the Tech World
Explore Sergei Brin's journey from a Moscow immigrant to co-founding Google, detailing key developments and Alphabet's creation.
29 Apr 2024
Four Decades of IPOs: An Overview
An overview of the stock and IPO market from the 80's until today, highlighting important events and trends.
24 Apr 2024
Larry Page: The Mastermind Behind Google
Explore the journey of Larry Page from a tech-savvy youth to co-founding Google and leading Alphabet.
24 Apr 2024
Ticker symbol
Country
🇳🇴 Norway